ACTA1 and steatosis: In db/db mice, EV infusion (db/db‐EVs) significantly reduced tissue injury, steatosis, and fibrosis, as evidenced by H&E staining and decreased positive areas for Oil Red O, Sirius Red, and α‐SMA (a marker of activated hepatic stellate cells) staining over 4–8 weeks post‐treatment (Figure 1F–I).